Aldeyra Therapeutics Reports First Patient Enrolment in the P-II Trial Evaluating ADX-629 in Atopic Dermatitis
Shots:
- The first patient was enrolled in the P-II clinical trial evaluating the safety & efficacy of ADX-629 monotx. (BID for 90days) vs in combination with SoC in adult patients with mild, moderate, or severe atopic dermatitis
- 10 patients will initially be evaluated in part 1 of the study by receiving open-label ADX-629 & the outcomes will be measured based on the improvement in Investigator Global Assessment and Eczema Area & Severity Index scores
- The part 1 results of the trial are expected by H2’23 based on which the patients in part 2 will be randomized to either ADX-629 or PBO. Additionally, ADX-629 is also being evaluated in other P-II clinical trials for chronic cough (results expected in H1’23), idiopathic nephrotic syndrome, and Sjögren-Larsson Syndrome
Ref: Businesswire | Image: Aldreya
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
